Table 1.
Participant and Epilepsy-Specific Descriptive Statistics (N = 50)
| Characteristics | Total Samplea (n=50) |
STAR Intervention (n=11) |
Treatment as Usual (n=12) |
High Adherence (n=22) |
|---|---|---|---|---|
| Child Age (mean ± SD) | 7.6 ± 3.0 | 6.4 ± 3.5 | 8.4 ± 3.1 | 7.4 ± 2.9 |
| Child Male (%) | 66.0 | 55.0 | 75.0 | 72.7 |
| Child Race (%) | ||||
| Caucasian | 86.0 | 81.8 | 83.3 | 90.9 |
| African-American | 12.0 | 18.2 | 16.7 | 9.1 |
| Biracial | 2.0 | 0.0 | 0.0 | 0.0 |
| Caregiver Relation to Child (%) | ||||
| Mothers | 84.0 | 90.9 | 66.7 | 90.9 |
| Fathers | 10.0 | 0.0 | 33.3 | 4.5 |
| Other (e.g., Uncle, Grandmother) | 6.0 | 9.1 | 0.0 | 4.5 |
| Caregiver Marital Status (%) | ||||
| Married | 57.1 | 63.6 | 33.0 | 68.2 |
| Single | 24.5 | 18.2 | 41.7 | 22.7 |
| Divorced | 18.4 | 18.2 | 25.0 | 9.1 |
| Socioeconomic Status (mean ± SD) b | 51.7 ± 21.3 | 45.5 ± 19.6 | 54.5 ± 22.3 | 59.0 ± 22.4 |
| Epilepsy Diagnosis (%) | ||||
| Idiopathic Localization-related | 42.0 | 63.6 | 33.3 | 40.9 |
| Idiopathic Generalized | 24.0 | 18.2 | 25.0 | 31.8 |
| Idiopathic Unclassified | 28.0 | 9.1 | 33.3 | 27.3 |
| Cryptogenic Generalized | 2.0 | 9.1 | 0.0 | 0.0 |
| Symptomatic Localization-related | 4.0 | 0.0 | 8.3 | 0.0 |
| Initial Prescribed Anti-Epileptic Drug (%) | ||||
| Carbamazepine | 32.0 | 63.6 | 25.0 | 18.2 |
| Valproic Acid | 30.0 | 27.3 | 33.0 | 27.3 |
| Levetiracetam | 24.0 | 9.1 | 41.7 | 22.7 |
| Ethosuximide | 8.0 | 0.0 | 0.0 | 18.2 |
| Other | 6.0 | 0.0 | 0.0 | 13.6 |
| Baseline Total Side effects score 11 | 11.4 ± 12.1 | 13.2 ± 13.9 | 7.5 ± 7.5 | 12.9 ± 13.9 |
| Seizure Presence in past 3 months | 36% | 18% | 16% | 59% |
a
Note: Five patients withdrew prior to randomization.